Pre-Conference III: Auditing, Monitoring and Effective Internal Investigations Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.

Slides:



Advertisements
Similar presentations
4.02 Compliance Training Brian A. Dahl Senior Counsel Takeda Pharmaceuticals North America, Inc. November 14, 2003.
Advertisements

Pharmaceutical Congress Spring 2003 Preconference Symposia Compliance 101 for Pharmaceutical Manufacturers Michael P. Swiatocha June 8, 2003.
EMS Checklist (ISO model)
Process and Procedure Documentation. Agenda Why document processes and procedures? What is process and procedure documentation? Who creates and uses this.
Internal Control–Integrated Framework
Auditing, Assurance and Governance in Local Government
Pharmaceutical Compliance Current Trends: Hot Button Issues to Look at this Year in Sales, Marketing, Clinical, Medical Affairs and Government Pricing.
Environmental Management System (EMS)
Introduction to Enterprise Risk Management (ERM)
Tax Risk Management Keeping Up with the Ever-Changing World of Corporate Tax March 27, 2007 Tax Services Bryan Slone March 27, 2007.
Environmental Management Systems An Overview With Practical Applications.
Internal Control. COSO’s Framework Committee of Sponsoring Organizations 1992 issued a white paper on internal control Since this time, this framework.
Office of Inspector General (OIG) Internal Audit
Purpose of the Standards
Supplier Ethics: Program Checklist
Corporate Ethics Compliance *
E XAMINATION AND E NFORCEMENT I SSUES : B EYOND T HE P ILLARS The AMLA Third Annual Full Day BSA/AML Conference October 4, 2013 Presented by: John M. Geiringer.
Elements of Internal Controls Preventing Fraud, Waste, and Abuse in Urban and Rural Transit Systems.
Control environment and control activities. Day II Session III and IV.
Internal Auditing and Outsourcing
Qantas Brand Refresh Kristy Dixon – Masters of Applied Project Management University of Adelaide 2013 Results of Risk Analysis Plan Hypothetical Project.
An Educational Computer Based Training Program CBTCBT.
1 Internal Controls. 2 Example Internal Control Manual  Focused Assessment Exhibit 4A  /trade/trade_programs/audits/focused.
ISMMMO, Antalya April Internal Audit, Best Practices Özlem Aykaç, CIA,CCSA CAE Coca-Cola İçecek.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
CORPORATE COMPLIANCE Tim Timmons Vice President Compliance and Regulatory Services Health Future, LLC.
NIST Special Publication Revision 1
Developing and Implementing an Effective Compliance Program Mary Sacilotto,BA,CHC Chief Compliance Officer Alliance, Inc.
Establishing A Compliance Program: It Makes Sense
How to Develop Internal Monitoring Programs SEVENTH ANNUAL PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS AND BEST PRACTICES FORUM Stephen F. Mohr Global.
Chapter 5 Internal Control over Financial Reporting
CDS Operational Risk Management - October 28, 2005 Existing Methodologies for Operational Risk Mitigation - CDS’s ERM Program ACSDA Seminar - October 26.
Introduction In 1992, the Committee Of Sponsoring Organizations of the Treadway Commission (COSO) published Internal Control-Integrated Framework (1992.
Internal Control in a Financial Statement Audit
© 2013 Cengage Learning. All Rights Reserved. 1 Part Four: Implementing Business Ethics in a Global Economy Chapter 9: Managing and Controlling Ethics.
Implementing and Auditing Ethics Programs
Pitfalls and Lessons Learned: Advanced Implementation Strategies for a Compliant Grant Process National CME Audioconference December 9, 2008.
Agency Risk Management & Internal Control Standards (ARMICS)
Module N° 8 – SSP implementation plan. SSP – A structured approach Module 2 Basic safety management concepts Module 2 Basic safety management concepts.
1 Strategies for a Compliant Grant Process CIA Monitoring Obligations A. Monica Jonhart Director-U S Pharmaceuticals Compliance Bristol-Myers Squibb.
1 Today’s Presentation Sarbanes Oxley and Financial Reporting An NSTAR Perspective.
Chapter 6 CRISIS MANAGEMENT. Introduction - Crisis: ◦is a situation that specifically involves a pharmaceutical product, medical device or activity with.
Private & Confidential1 (SIA) 13 Enterprise Risk Management The Standard should be read in the conjunction with the "Preface to the Standards on Internal.
ISO GENERAL REQUIREMENTS. ISO Environmental Management Systems 2 Lesson Learning Goals At the end of this lesson you should be able to: 
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
Risk Management & Corporate Governance 1. What is Risk?  Risk arises from uncertainty; but all uncertainties do not carry risk.  Possibility of an unfavorable.
Strategic Approaches to Improving Ethical Behavior
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
Setting the Scene: The Role of Ethics and Compliance in the Biopharmaceutical Market.
McGraw-Hill/Irwin © 2003 The McGraw-Hill Companies, Inc., All Rights Reserved. 6-1 Chapter 6 CHAPTER 6 INTERNAL CONTROL IN A FINANCIAL STATEMENT AUDIT.
Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Special Program for Internal/Compliance Audit Professionals: Enterprise Risk.
1 1 Auditing: A Panel Discussion of Evolving Compliance Strategies Ann E Lewis, VP and Senior Counsel, US Healthcare Law Compliance (Bristol-Myers Squibb)
Agenda for Session Compliance in Clinical Research
Chief Compliance Officer
Company: Cincinnati Insurance Company Position: IT Governance Risk & Compliance Service Manager Location: Fairfield, OH About the Company : The Cincinnati.
Chapter 8 Auditing in an E-commerce Environment
Building A Pharmaceutical Compliance Program Presentation to the Sixth Annual Congress on Health Care Compliance February 7, 2003 Janice Toran Fujisawa.
1 Compliance vs. the Law Department: How to Work Together Michael Dusseau Senior Director, Compliance North America Schering-Plough David Ralston, Esq.
0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
Revision N° 11ICAO Safety Management Systems (SMS) Course01/01/08 Module N° 9 – SMS operation.
Valiants Verify Compliance Program Judith W. Spain, J.D., CCEP ® Chief Ethics and Compliance Officer General Counsel (Effective March 2016) 1.
Internal Audit Section. Authorized in Section , Florida Statutes Section , Florida Statutes (F.S.), authorizes the Inspector General to review.
1 Vereniging van Compliance Officers The Compliance Function in Banks Amsterdam, 10 June 2004 Marc Pickeur CBFA CBFA.
MGMT 452 Corporate Social Responsibility
Understanding the Principles and Their Effect on the Audit
Построение культуры integrity в компании Aнар Каримов партнёр «ЭКВИТА»
The Most Important Element to Assure That Your Sales and Marketing Compliance Program is Working Effectively: Monitoring and Auditing Kelly B. Freeman,
The Role of Internal Audit in Health Care Compliance
Risk Management: why and how to protect your health center
Presentation transcript:

Pre-Conference III: Auditing, Monitoring and Effective Internal Investigations Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum October 27, 2008

Pre-Conference III: Auditing, Monitoring and Effective Internal Investigations Implementing a Compliance Monitoring Program Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum October 27, 2008

Implementing a Compliance Monitoring Program 3 Agenda Introductions Implementing a Compliance Monitoring Program Understanding the differences between monitoring and auditing Establishing an effective compliance monitoring program Case Study: Use of monitoring tools Q & A

Implementing a Compliance Monitoring Program 4 Presenters Christopher Santarcangelo, Assistant Director of Corporate Compliance, Purdue Pharma L.P. Jonathan Williams, Associate Director, Healthcare Compliance Office, Genentech, Inc. Tracy Mastro, Director, Huron Consulting Group

Implementing a Compliance Monitoring Program 5 Compliance Monitoring and Auditing

Implementing a Compliance Monitoring Program 6 Compliance Monitoring and Auditing One of the seven key elements of an effective Corporate Compliance program (HHS Office of Inspector General) Facilitates the identification and mitigation of compliance risks and improvement of internal controls Should be used to: –Measure and benchmark a Compliance program’s effectiveness and impact on business activities –Document Company’s compliance with internal written controls 6

Implementing a Compliance Monitoring Program 7 Compliance Monitoring and Auditing May be used to test the execution and effectiveness of functions at the core of a Compliance program, such as: – Compliance training – Employee and vendor screening – Disciplinary actions Should be used to measure a Compliance program’s progress in attaining higher levels of compliance as the program matures 7

Implementing a Compliance Monitoring Program 8 Key Objectives of Monitoring and Auditing AuditingMonitoring 1.Purpose Retrospective Processes and procedures comply with laws, regulations, policies Retrospective or prospective (live) Daily activities to assess achievement of objectives 2.Scope/ Focus Internal controls and processes related to general business standards/policies Activities and transactions related to specific function/process/dept Internal and external focus 3.Activities Periodic, structured reviews Conducted by independent staff Validate/measure performance Business units self-monitor 4.Frequency Determined by risk-based audit plan “Snapshot” in time Determined by frequency of transactions Ongoing process 5.Reporting Formal audit report with findings and recommendations Variance analysis, exception reporting, performance metrics 8

Implementing a Compliance Monitoring Program 9 The Monitoring and Auditing Cycle Establish/Revise Policy Develop Processes (system and non-system) Train on Policies and Processes Develop Auditing and Monitoring Programs Monitor Processes and Conduct Audits Assess and Report Results/Findings Revise Processes, Training, Systems 9

Implementing a Compliance Monitoring Program 10 Establishing an Effective Compliance Monitoring Program

Implementing a Compliance Monitoring Program 11 Establishing a Monitoring Program Establish Foundation Design and Execution Assess and Report Assess and Report  Tone from the Top  Organization Structure  Baseline Understanding of the Effectiveness of Internal Controls  Additional Internal Controls Implemented (if necessary)  Tone from the Top  Organization Structure  Baseline Understanding of the Effectiveness of Internal Controls  Additional Internal Controls Implemented (if necessary)  Prioritize Compliance Risks  Identify Relevant Operating Controls  Identify Individuals Responsible for Monitoring  Design and Implement Monitoring Procedures  Prioritize Compliance Risks  Identify Relevant Operating Controls  Identify Individuals Responsible for Monitoring  Design and Implement Monitoring Procedures  Prioritize and Report Results and Findings  Identify Correction Action(s) and Follow- Up  Assign Individuals Responsible for Corrective Action  Prioritize and Report Results and Findings  Identify Correction Action(s) and Follow- Up  Assign Individuals Responsible for Corrective Action 11

Implementing a Compliance Monitoring Program 12 Establishing a Monitoring Program Monitoring should be based on: –A fundamental analysis of compliance and business risks, and –An understanding of how key controls may/may not manage or mitigate risks Monitoring procedures also should be based on a Company’s unique compliance risk profile –Prioritization of risks helps identify which risks are meaningful enough to subject to compliance monitoring –Results of risk assessments will influence decisions regarding the type, timing, and extent of monitoring Design and Execution 12

Implementing a Compliance Monitoring Program 13 Establishing a Monitoring Program 13 Assessing Compliance Risks

Implementing a Compliance Monitoring Program 14 Establishing a Monitoring Program Monitoring should reflect a Company’s internal written controls and control structure Determine the key controls that are important in managing or mitigating identified compliance risks –Key controls are those that are most important to monitor –A focus on key controls helps ensure that the Company devotes monitoring resources efficiently and where they will provide the most value Design and Execution (cont’d) 14

Implementing a Compliance Monitoring Program 15 Establishing a Monitoring Program Speakers & Consultants State Reporting Submissions Clinical Research Gov’t Price Reporting HCP Meals External Drivers CIA Regulatory Legal Enforcement Action Industry Standards Public Opinion Media/Press Internal Drivers Organizational Structures Organizational Change Operational Exposure - Complexity - Automation - Committed Resources - Recent Changes Self-Assessment Historical Audit Results Technology Capabilities Dissemination of Scientific Information Continuing Medical Education 15 Prioritizing Monitoring Resources

Implementing a Compliance Monitoring Program 16 Establishing a Monitoring Program Monitoring procedures should be developed to reflect a Company’s unique risk profile. For example: –Older products may represent kickback issues Not much clinical discussion with sales representatives Services offered to customers could be used to influence prescribing (e.g., grants, promotional speaking) –New products may represent off-label promotion risks Dosing Product used in combination with other therapies Design and Execution (cont’d) 16

Implementing a Compliance Monitoring Program 17 Establishing a Monitoring Program There are different way to measure risk. For example: –Number of statutory/regulatory violations Kickbacks (e.g., payments to HCPs, marketing the spread) Off-Label activities (e.g., requests for off-label information) – Number of policy violations Compliance issues with policies (e.g., promotional speaker programs) Compliance issues with processes (e.g., state reporting requirements on Travel & Expense reports) Design and Execution (cont’d) 17

Implementing a Compliance Monitoring Program 18 Establishing a Monitoring Program Results of monitoring should either: –Confirm previously established expectations about the effectiveness of internal controls, or –Highlight identified deficiencies for possible corrective action Results should be compiled, analyzed and reported to appropriate personnel for information and/or action Assess and Report 18

Implementing a Compliance Monitoring Program 19 Establishing a Monitoring Program Properly designed and executed, effective monitoring programs: –Provide the right information to the right people (e.g., Compliance, business units) regarding effectiveness Effectiveness defined through identification of criteria, measures, and metrics –Identify and communicate internal control deficiencies in a timely manner –Facilitate the correction of control deficiencies before they materially affect the achievement of a Company’s objectives Effective Programs 19

Implementing a Compliance Monitoring Program 20 Case Study: Use of Monitoring Tools

Implementing a Compliance Monitoring Program 21 Case Study Objectives The objectives of the Case Study are to: –Provide examples of situations in which monitoring may be used, and –How monitoring tools are used to determine whether compliance issues exist 21

Implementing a Compliance Monitoring Program 22 Case Study Scenario Company X recently a new Oncology product launch in January 2008 –The new product was approved for Lung cancer –There are studies that show the product’s potential effectiveness in Thoracic cancer, an off-label use The product’s Brand Plan reflects that Company X has been using promotional speaker programs, Advisory Board meetings, and CME to inform physicians about its new product 22

Implementing a Compliance Monitoring Program 23 Case Study: Monitoring Activities Medical Communications During the ongoing Medical Communications monitoring process, the Compliance unit discovered a spike in requests for off-label information for Product X in March of 2008 Compliance looked at the monitoring data for requests coming in since January 2008 and identified the following trends 23

Implementing a Compliance Monitoring Program 24 No. of Requests 2008 Case Study: Monitoring Activities Medical Information Requests by Product 24

Implementing a Compliance Monitoring Program 25 Case Study: Monitoring Activities 2008 No. of Requests Requests by Product X Sales Rep 25

Implementing a Compliance Monitoring Program 26 Case Study: Monitoring Activities Important Data Reference Points Requests for off-label information – Dates of conferences/meetings – Trends in requests (e.g., by region, sales rep) – MSL activities – Other activities in region – Internal communications to sales force Advisory Board meetings Promotional Speaker programs Continuing Medical Education meetings 26

Implementing a Compliance Monitoring Program 27 Case Study: Monitoring Activities Sales Representative Ride-Along Inform Sales Rep and DM of ride-along Compliance monitor identified generically as being from “home office” Sales Rep behaviors monitored: –Conversations with DM –Interactions/discussions with physician(s), nurses and office staff Discussions of grants, CME programs, sponsorships, other consulting opportunities –Comments made by physicians, nurses and/or office staff to sales rep –Use of reprints/other leave behind materials 27

Implementing a Compliance Monitoring Program 28 Questions? Tracy Mastro Jonathan Williams, Esq Chris Santarcangelo